Merck signed an exclusive global licensing deal with China-based SciBrunch Therapeutics for a preclinical KRAS G12D (on) inhibitor program, paying $400 million upfront and valuing the agreement at $2.13 billion if milestones are met. The deal provides Merck global rights to SPR-2015, aimed at blocking mutated KRAS in its active state. The move reflects continued pharma focus on KRAS G12D as a strategy to reach previously difficult targets. The preclinical stage adds a longer execution runway but can strengthen Merck’s oncology pipeline well before clinical readouts. The article frames the licensing decision in the context of prior negotiations between Merck and other KRAS-related assets that did not proceed to an agreement. It also places Merck among multiple companies making sizeable bets on KRAS G12D programs. For investors and pipeline planners, the deal is a clear signal that Merck intends to maintain optionality in a crowded KRAS landscape rather than relying on a single internal approach.